Description: A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
Mechanism of Action: antibody drug conjugate to ALPP (placental alkaline phosphatase) and ALPP2 (human alkaline phosphatase, placental like-2). These are tumor antigens present on below cancers
Target Patient Population: Ovarian, Endometrial, Non Small Cell Lung Cancer, Gastric, Cervical, Testicular cancers, Ovarian germ cell tumors
Study Design: Drug is administered IV Day 1, 8 of a 21 day cycle. Alternative schedules may be considered.